Inogen (INGN) Return on Capital Employed (2014 - 2026)
Inogen's (INGN) quarterly Return on Capital Employed came in at 13.81% in Q1 2026, up 50.0% year-on-year from 9.21% in Q1 2025, and down 9.43% on a QoQ basis from 12.62% in Q4 2025.
Inogen (INGN) Return on Capital Employed (2014 - 2026) Analysis & Trends
Inogen (INGN) has 13 years of Return on Capital Employed data on file, last reported at 13.81% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 50.0% year-over-year to 13.81% in Q1 2026; TTM through Mar 2026 was 13.81%, a 50.0% increase from a year earlier, with the FY2025 full-year figure at 12.92%, up 521.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 13.81%, down from 12.62% in the prior quarter.
- Over the last five years, Return on Capital Employed for INGN reached as high as 0.52% in Q1 2022 and fell as low as 46.51% in Q3 2023.
- Historically, Return on Capital Employed has averaged 22.32% across 5 years, with a median of 18.94% in 2024.
- Across the five-year window, Return on Capital Employed plunged 3824 bps in 2023 and jumped 2770 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 22.92% in 2022, then tumbled by 82 bps to 41.68% in 2023, then soared by 55 bps to 18.94% in 2024, then jumped by 33 bps to 12.62% in 2025, then fell by 9 bps to 13.81% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 13.81% in Q1 2026, 12.62% in Q4 2025, and 13.2% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Inogen | 172.68 Mn | 62.51 Mn | 37.86 Mn | -13.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.81% |
| Dec 31, 2025 | -12.62% |
| Sep 30, 2025 | -13.20% |
| Jun 30, 2025 | -13.56% |
| Mar 31, 2025 | -14.31% |
| Dec 31, 2024 | -18.94% |
| Sep 30, 2024 | -25.56% |
| Jun 30, 2024 | -41.25% |
| Mar 31, 2024 | -42.00% |
| Dec 31, 2023 | -41.68% |
| Sep 30, 2023 | -46.51% |
| Jun 30, 2023 | -31.96% |
| Mar 31, 2023 | -28.19% |
| Dec 31, 2022 | -22.92% |
| Sep 30, 2022 | -8.27% |
| Jun 30, 2022 | -4.06% |
| Mar 31, 2022 | -0.52% |
| Dec 31, 2021 | 2.10% |
| Sep 30, 2021 | 2.33% |
| Jun 30, 2021 | 0.48% |